))
Risk of eye damage in patients with SLE and RA taking hydroxychloroquine
Manage episode 446536568 series 3610272
Contenu fourni par Arthritis Consumer Experts. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Arthritis Consumer Experts ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode of Arthritis At Home, Cheryl Koehn, Founder and President at Arthritis Consumer Experts, speaks to Dr. J. Antonio Aviña-Zubieta, UBC Division Head of Rheumatology, BC Lupus Society Research Scholar, and Senior Scientist at Arthritis Research Canada. They discuss the INTACT study, an ongoing study working to determine the risk of eye damage in people with systemic lupus erythematosus and rheumatoid arthritis who are taking hydroxychloroquine.
If you are interested in participating in this study, please ask your rheumatologist to refer you for an annual retina screening test as part of the INTACT study during your upcoming visit. To learn more about the study, please email the team at [email protected]
Additional learning resources
- Current Research: Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy
- Learn more about hydroxychloroquine therapy in SLE and RA
- Learn more about lupus at Arthritis Consumer Experts’ About Lupus page
- Learn more about rheumatoid arthritis at Arthritis Consumer Experts’ About Rheumatoid Arthritis page
130 episodes
Partager
